(Q34276645)

1 August 2017

title

Belimumab and the clinical data (English)

1 reference

1 August 2017

1 reference

Katrina Shum

1

1 reference

1 August 2017

Anca Askanase

series ordinal

2

1 reference

1 August 2017

publication date

1 August 2012

1 reference

Current Rheumatology Reports

1 August 2017

published in

1 reference

1 August 2017

volume

14

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

310-317

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-012-0264-4

1 August 2017

exact match

0 references

cites work

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-012-0264-4

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

12 December 2020

Population-based lupus registries: Advancing our epidemiologic understanding

1 reference

12 December 2020

Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus

1 reference

12 December 2020

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

12 December 2020

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

1 reference

12 December 2020

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

1 reference

12 December 2020

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

12 December 2020

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

1 reference

12 December 2020

Novel evidence-based systemic lupus erythematosus responder index

1 reference

12 December 2020

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

12 December 2020

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

1 reference

12 December 2020

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

12 December 2020

Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study

1 reference

12 December 2020

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

1 reference

12 December 2020

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

1 reference

12 December 2020

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

12 December 2020

The role of B cells in lupus pathogenesis

1 reference

12 December 2020

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study

1 reference

12 December 2020

Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.

1 reference

12 December 2020

Mortality in systemic lupus erythematosus

1 reference

12 December 2020

The use of laboratory tests in the diagnosis of SLE

1 reference

12 December 2020

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

1 reference

12 December 2020

An international cohort study of cancer in systemic lupus erythematosus

1 reference

12 December 2020

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

12 December 2020

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

1 reference

12 December 2020

10.1007/S11926-012-0264-4

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1014263470

0 references

1 reference